Risdiplam (BioDeep_00000858623)
代谢物信息卡片
化学式: C22H23N7O (401.1963988)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
InChI: InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3
描述信息
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents
C78272 - Agent Affecting Nervous System
M - Musculo-skeletal system
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11406
- PubChem: 118513932
- DrugBank: DB15305
- ChEMBL: CHEMBL4297528
- CAS: 1825352-65-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lurong Yu, Limei Liu. Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
PloS one.
2024; 19(3):e0298609. doi:
10.1371/journal.pone.0298609. [PMID: 38427665] - Heidemarie Kletzl, Hassan Ajmi, Izabela Antys, Katja Heinig, Birgit Jaber, Thomas C Marbury, Annie Young, Andreas Günther. Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam.
British journal of clinical pharmacology.
2022 Aug; 88(8):3749-3759. doi:
10.1111/bcp.15319. [PMID: 35301746] - Jennifer M Kwon, Kapil Arya, Nancy Kuntz, Han C Phan, Cory Sieburg, Kathryn J Swoboda, Aravindhan Veerapandiyan, Beverly Assman, Silvia Bader-Weder, Travis L Dickendesher, Jennifer Hansen, Helen Lin, Ying Yan, Vamshi K Rao. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.
Annals of clinical and translational neurology.
2022 06; 9(6):810-818. doi:
10.1002/acn3.51560. [PMID: 35567422] - Michael S Cartwright, Suraj Upadhya. Selecting disease-modifying medications in 5q spinal muscular atrophy.
Muscle & nerve.
2021 Oct; 64(4):404-412. doi:
10.1002/mus.27358. [PMID: 34231920] - Stefan Sturm, Andreas Günther, Birgit Jaber, Paul Jordan, Nada Al Kotbi, Nikhat Parkar, Yumi Cleary, Nicolas Frances, Tobias Bergauer, Katja Heinig, Heidemarie Kletzl, Anne Marquet, Hasane Ratni, Agnès Poirier, Lutz Müller, Christian Czech, Omar Khwaja. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
British journal of clinical pharmacology.
2019 01; 85(1):181-193. doi:
10.1111/bcp.13786. [PMID: 30302786] - Agnès Poirier, Marla Weetall, Katja Heinig, Franz Bucheli, Kerstin Schoenlein, Jochem Alsenz, Simon Bassett, Mohammed Ullah, Claudia Senn, Hasane Ratni, Nikolai Naryshkin, Sergey Paushkin, Lutz Mueller. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
Pharmacology research & perspectives.
2018 12; 6(6):e00447. doi:
10.1002/prp2.447. [PMID: 30519476]